Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Feb 11;25(1):244.
doi: 10.1186/s12885-025-13590-6.

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors

Gwenn Le Gall #  1   2 , François Cherifi #  2   3 , Jordane Divoux  1   4   5 , Romane Florent  5 , François Christy  2 , Alexandra Leconte  2 , Chankannira San  2 , Amélie Devillers  2 , Guillaume Desmartin  4   5 , Lucie Lecouflet  4   5 , Bénédicte Clarisse  2 , Samantha Ballesta  6 , Lucie Thorel  1   4 , Brice Dubois  7 , Valentin Harter  7 , Nathalie Rousseau  8 , Léopold Gaichies  9 , Sandrine Martin-Françoise  9 , Jean-François Le Brun  9 , Enora Dolivet  1   9 , Roman Rouzier  9 , Corinne Jeanne  10 , Cécile Blanc-Fournier  1   8   10 , Martin Figeac  11 , Raphaël Leman  3 , Laurent Castera  3 , Laurent Poulain  1   4   5 , Louis-Bastien Weiswald #  12   13   14 , Florence Joly #  15
Affiliations
Observational Study

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors

Gwenn Le Gall et al. BMC Cancer. .

Abstract

Background: Combination of chemotherapy and immunotherapy is the current standard of care for advanced endometrial cancer. However, survival outcome remains poor, highlighting the urgent need for new treatments and reliable tools to identify patients who will benefit from them. Patient-Derived Tumor Organoids (PDTO) are three-dimensional structures established from patient tumors, and are closely mimicking the features of the tumor of origin. Moreover, more and more evidences show that PTDOs hold promises as predictive tools for the response to treatment of patients.

Method: The PENDOR study is a monocentric observational study designed to assess the feasibility of generating and testing PDTOs derived from endometrial cancer for evaluating treatment sensitivity. PDTOS will be established from surgical specimens not required for anatomopathological diagnosis. Tumor cells will be dissociated, embedded in extracellular matrix, and cultured in a medium supplemented with growth factors and signaling pathways inhibitors. Molecular and histological analyses will be conducted to validate the resemblance of PDTO to the original tumor. Response of PDTO to conventional chemotherapy and PARP inhibitors will be evaluated and compared to clinical response and to the results of an academic HRD test Genomic Instability Scar (GIScar), respectively, to assess their predictive value.

Discussion: This pilot study aims to validate the feasibility to develop PDTOs from endometrial cancer from patients who will undergo surgical resection. We aim to provide a proof of concept regarding the predictive value of these models for their potential application into routine clinical practice as part of precision medicine. This approach could therefore facilitate the identification of patients who could benefit from PARP inhibitors.

Trial registration: This clinical trial (N°ID-RCB: 2024-A01206-41) has been validated by local research ethic committee on July 16th 2024 and registered at ClinicalTrials.gov with the identifier NCT06603506 on September 6th 2024, version 1.

Keywords: Endometrial cancer; Homologous recombination deficiency; PARP inhibitors; Patient-derived tumor organoids; Predictive functional assays.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study has received ethical approval from the « West II » ethical commitee (IDRCB: 2024-A01206-41) on July 16th, 2024. This committee is independent and not related with any affiliation of the authors. Any subsequent will of modification of the protocol would be submitted for approval from the committee. The clinical trial has been registered registered at ClinicalTrials.gov with the identifier NCT06603506 on September 19th, 2024. The study will be explained to the patients by the surgeons or the medical oncologists and an informed consent form will be obtained from all participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PENDOR study design
See this image and copyright information in PMC

References

    1. GLOBOCAN W. Cancer Today. [cited 2024 Oct 30]. Available from: https://gco.iarc.fr/today/en/dataviz/tables?mode=population&cancers=24&t...
    1. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. - PMC - PubMed
    1. Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2022;33(9):860–77. - PubMed
    1. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the Anti-programmed Death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial Cancer: a Nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–72. - PMC - PubMed
    1. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data